Cargando…
Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review
The fully human monoclonal antibody denosumab was approved for treatment of osteoporosis in 2010 on the basis of its potent antiresorptive activity, which produces clinically meaningful increases in bone mineral density (BMD) and reduces fracture risk at key skeletal sites. At that time, questions r...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799550/ https://www.ncbi.nlm.nih.gov/pubmed/34762286 http://dx.doi.org/10.1007/s12325-021-01936-y |